Mo. Attorney General sends prescription manufacturer Eli Lilly cease-and-desist over drug price policy

The Missouri Attorney General has issued a formal cease-and-desist letter to the prescription drug manufacturer Eli Lilly. This legal action follows a pricing dispute involving MU Health Care. According to reporting from STAT, the Attorney General is specifically warning Eli Lilly to stop its practice of requiring data from hospitals that are seeking drug discounts under the 340B program. This move marks a significant escalation in the conflict between the state's legal office and the pharmaceutical company regarding how drug discounts are administered and accessed by healthcare providers. Coverage of this development is being tracked by multiple regional and specialized outlets. KMOV and KOMU 8 have both reported on the issuance of the cease-and-desist letter, while ABC17NEWS highlights that the friction began with a pricing spat involving MU Health Care.

STAT provides further technical detail regarding the specific data requirements Eli Lilly has imposed on hospitals. Additionally, Law360 identifies this as part of a larger landscape of legal conflicts, categorizing it as one of the critical cases to watch within the broader 340B battles currently unfolding in the legal system. To understand the stakes of this conflict, it is necessary to look at the wider legal challenges facing Eli Lilly. The Boston Globe reports that several hospitals, including Massachusetts General Hospital (MGH) and Brigham and Women's Hospital, have filed lawsuits against the company. These healthcare institutions allege that Eli Lilly's conduct within the drug discount program constitutes extortion. The 340B program is designed to provide discounts on drugs to eligible providers, but disputes over the manufacturer's right to demand specific data from these hospitals have led to these systemic legal challenges.

Moving forward, the situation will likely depend on Eli Lilly's response to the Missouri Attorney General's warning and the outcome of the aforementioned lawsuits. Observers are monitoring whether the pharmaceutical company will alter its data requirements for hospitals seeking 340B discounts. Because Law360 has flagged these as high-priority cases to watch, the resolution of the disputes involving MGH and Brigham may set a precedent for how the Missouri cease-and-desist is handled. Coverage does not yet specify if further state-level litigation is planned beyond the initial warning letter.